NCT02676739View on ClinicalTrials.gov

Adderall XR and Cognitive Impairment in MS

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

May 20, 2016

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions
Multiple Sclerosis
Interventions
DRUG

Adderall XR

Trial Locations (3)

T6G 2G3

Kaye Edmonton Clinic, Edmonton

N6A 5A5

London Health Sciences Centre, London

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
lead

Sarah Morrow

OTHER

NCT02676739 - Adderall XR and Cognitive Impairment in MS | Biotech Hunter | Biotech Hunter